Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Notebook: Accelerated Ebola Reviews; EMA Remains In Health Directorate; Ireland’s Patent Box

Executive Summary

EMA expert group will advise Ebola developers and agency will accept rolling submissions; Irish aims to lure research-based firms with patent box, while Swedish pharma stakeholders call for investments and policy changes to bring back innovative companies.

You may also be interested in...



Ebola Treatments Could Be Orphan Candidates – But Vaccines, Probably Not

FDA expects few people would get the disease in the U.S., but many could receive a vaccine.

Ebola Threat Prompts EU To Focus On Adaptive Licensing

The spread of Ebola to Europe is prompting regulators and industry to explore in more detail adaptive licensing pathways to speed access to potentially life-saving drugs.

Rivalry Intensifies In Europe For Biotech Funding, Product Development

U.K. biotech companies lead Europe in terms of funds raised and products in development in the first half of 2014, but other countries in the region are not far behind.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel